Echo Pharmaceuticals
Echo Pharmaceuticals B.V. is a Netherlands-based pharmaceutical company specializing in extraction, purification, and formulation of cannabinoid compounds, supplying cGMP-grade reference standards and APIs to global R&D organizations while developing patented THC (Namisol) and CBD (Arvisol) oral tablets.
- Company typePrivate
- Founded2006
- HeadquartersLeiden, Netherlands
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Echo Pharmaceuticals does
Echo Pharmaceuticals B.V. is a private pharmaceutical company headquartered in Leiden, the Netherlands, founded in 2006. The company specializes in the extraction, purification, and formulation of lipophilic active compounds, with a domain focus on cannabinoids. Operating with a headcount of 11–50 employees, it serves R&D organizations worldwide through two product categories: (1) commercially available products — high-quality cannabinoid reference standards and cannabis-derived active pharmaceutical ingredients (APIs) produced under cGMP guidelines, and (2) products in clinical development — Namisol, a patented oral tablet containing pure natural Δ9-THC, and Arvisol, a patented oral tablet containing pure natural Cannabidiol (CBD), both engineered for high/predictable bioavailability and room-temperature shelf stability.
The company's underlying technology is built on proprietary knowledge of extracting and purifying arbitrary APIs from plant materials under controlled laboratory conditions, combined with patented drug formulation expertise. Its clinical-stage assets (Namisol and Arvisol) and patented formulation technology constitute the core intellectual property. The business model is direct B2B sales of reference standards and APIs to R&D organizations globally; no pricing is publicly disclosed, and no revenue, funding-round, or partnership data were available in the source material. The company's two clinical-stage candidates remain in development, meaning near-term commercial revenue depends primarily on reference-standard and API supply, with the larger pharmaceutical upside tied to clinical trial outcomes and eventual commercialization of Namisol and/or Arvisol.
Echo Pharmaceuticals firmographics
Firmographics- Name
- Echo Pharmaceuticals
- Legal name
- Echo Pharmaceuticals B.V.
- Website
- https://echo-pharma.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Echo Pharmaceuticals B.V. is a Netherlands-based pharmaceutical company specializing in extraction, purification, and formulation of cannabinoid compounds, supplying cGMP-grade reference standards and APIs to global R&D organizations while developing patented THC (Namisol) and CBD (Arvisol) oral tablets.
- Ownership category
- akta.pro rank
Where Echo Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Leiden
- HQ country
- Netherlands
- HQ region
- Europe
Offices1 record
Markets served
Echo Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales
Distribution channels1 record
Echo Pharmaceuticals product offering
Product offeringCore offering
Echo Pharmaceuticals extracts, purifies, and formulates cannabinoid-based active pharmaceutical ingredients (APIs) and reference standards under cGMP guidelines, supplying them to R&D organizations worldwide. Its commercial portfolio includes a wide range of high-quality cannabinoid reference standards and cannabis-derived APIs, and it is advancing two patented oral tablet formulations — Namisol (Δ9-THC) and Arvisol (Cannabidiol) — through clinical development.
Product overview
Echo Pharmaceuticals offers a portfolio of drug delivery technologies and cannabinoid-based medicines. The product lineup consists of two product categories: (1) Products on Market — Reference Standards (high-quality analytical standards) and Active Pharmaceutical Ingredients (cannabis-derived APIs produced under cGMP); and (2) Products in Clinical Development — Namisol (oral tablet with Δ9-THC) and Arvisol (oral tablet with Cannabidiol), both patented formulations with optimized bioavailability and room-temperature shelf stability. The company leverages proprietary expertise in extraction, purification, and formulation of lipophilic active compounds from plant materials.
Differentiator
Problem solved
Functional benefit
Companies that use Echo Pharmaceuticals
Customer profileSegments1 record
Ideal customer profiles1 record
Echo Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Echo Pharmaceuticals partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights3 records
Echo Pharmaceuticals competitors and assessment
Company assessmentOthers
Direct peers
- Bedrocan: Long-established Dutch medical-grade cannabis producer supplying standardized cannabis APIs to pharmacies and research organizations across Europe. Comparable as a specialty cannabinoid API supplier operating in GMP frameworks.
- InMed Pharmaceuticals: Clinical-stage pharmaceutical company developing cannabinoid-based therapies using proprietary manufacturing and formulation approaches. Comparable to Echo as a small-cap pure-play cannabinoid pharma developer with API/finished-dose focus.
- Tetra Bio-Pharma: Canadian cannabinoid-derived drug developer focused on prescription cannabinoid medicines. Comparable in developing clinically validated, pharmaceutical-grade cannabinoid dosage forms for specific therapeutic indications.
- Botanix Pharmaceuticals: Clinical-stage pharmaceutical company developing proprietary cannabinoid-based therapies with novel delivery technologies. Directly comparable to Echo's Namisol/Arvisol approach of formulating cannabinoids into patient-friendly dosage forms.
- Jazz Pharmaceuticals (GW Pharmaceuticals): Jazz acquired GW Pharmaceuticals, developer of cannabinoid-based medicines including Sativex and Epidiolex (CBD). Most directly comparable peer for Echo's cannabinoid pharma development model, particularly for CBD-based finished dosage forms like Arvisol.
Emerging players
- Emerald Health Therapeutics: Canadian company developing cannabinoid-based prescription medicines and pharma-grade cannabinoid APIs. Comparable as a smaller specialty player targeting pharmaceutical customers in cannabinoid drug development.
- Demetrix (acquired by Antheia): Used synthetic biology and fermentation to produce pharmaceutical-grade cannabinoids at scale, targeting the same high-purity API market Echo serves with plant-derived extraction. Represents an alternative technological pathway for cannabinoid API supply.
Broad incumbents
- Canopy Growth Corporation: Major global cannabis operator with pharmaceutical-grade production capabilities, Spectrum Therapeutics medical portfolio, and clinical CBD research. Represents a much larger scaled competitor with overlapping API supply ambitions.
- Tilray Brands: Large Canadian cannabis company with pharmaceutical, wellness, and consumer operations across multiple geographies. Relevant incumbent for the broader cannabinoid API and finished-product market in which Echo competes.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Echo Pharmaceuticals compliance and trust
Trust signalCompliance1 record
Echo Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Echo Pharmaceuticals leadership team
Management profileNumber of profiles
Echo Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Echo Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Echo Pharmaceuticals
What does Echo Pharmaceuticals do?
Echo Pharmaceuticals extracts, purifies, and formulates cannabinoid-based active pharmaceutical ingredients (APIs) and reference standards under cGMP guidelines, supplying them to R&D organizations worldwide. Its commercial portfolio includes a wide range of high-quality cannabinoid reference standards and cannabis-derived APIs, and it is advancing two patented oral tablet formulations — Namisol (Δ9-THC) and Arvisol (Cannabidiol) — through clinical development.
Is Echo Pharmaceuticals a public or private company?
Echo Pharmaceuticals is a private company. It is classified as unknown and is currently operating.
When was Echo Pharmaceuticals founded?
Echo Pharmaceuticals was founded in 2006. It employs 11 to 50 people.
Where is Echo Pharmaceuticals based?
Echo Pharmaceuticals is headquartered in Leiden, Netherlands, in the Europe region.
Who are Echo Pharmaceuticals's main competitors?
Aurora Cannabis is listed as an others. Direct peers are Bedrocan, InMed Pharmaceuticals, Tetra Bio-Pharma, Botanix Pharmaceuticals and Jazz Pharmaceuticals (GW Pharmaceuticals). Emerging players are Emerald Health Therapeutics and Demetrix (acquired by Antheia). Broad incumbents are Canopy Growth Corporation and Tilray Brands.
Does Echo Pharmaceuticals have an API?
No public API is recorded for Echo Pharmaceuticals.